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Background:  Flow mediated dilation (FMD) is a widely used tool to investigate endothelial function. During a recent study aimed at assessing 
the reproducibility of brachial FMD we noticed that FMD measured shortly (15 minutes) after the first test tended to be lower than the first FMD. 
Furthermore, we also assessed whether L-arginine, the substrate for NO production by endothelial cells, could influence this variation.
Methods:  We enrolled 20 healthy subjects without any cardiovascular risk factors (26±6 years; 12 males). FMD was assessed by measuring 
brachial artery dilation in response to active hyperemia after 5 minutes of forearm cuff inflation. All subjects were studied in two subsequent days. 
On day 1 the subjects underwent two consecutive measures of FMD, with the second test (FMD2) performed 15 minutes after recovery of brachial 
artery diameter and flow velocity to basal levels after the first test (FMD1). On day 2, the subjects were randomized to receive either placebo (saline) 
or intravenous L-arginine (10 g, diluted in 250 cc of saline and administrated in 20 minutes). At the end of the infusion, patients underwent 2 
consecutive FMD measures following the same protocol of day 1.
Results:  On day 1, FMD2 was significantly lower than FMD1 in both groups (6.47±2.1 vs 7.86±1.8 in the placebo group, p<0.001; 6.13±2.6 vs 
7.76±2.7 in the arginine group, p=0.005). On day 2, a significant reduction of FMD was observed again during the second test, compared to the 
first one, in the placebo group (5.82±1.7 vs 7.44±2.2, p<0.001), whereas no significant differences between FMD1 and FMD2 were observed in the 
arginine group (7.19±1.5 vs 7.27±1.5, p=0.67). The increase of brachial artery flow velocity was similar during FMD1 and FMD2 assessment in the 
two groups.
Conclusions:  We observed a significant impairment of endothelial function immediately after the assessment of FMD. Intravenous L-arginine was 
able to prevent this impairment, suggesting that a reduced NO release is involved in this phenomenon.
